Brief: Finch Therapeutics Announces Removal Of FDA Clinical Hold On CP101 IND

Finch Therapeutics

28/04/2022 23:05

April 28 (Reuters) - Finch Therapeutics Group Inc  FNCH.O :
    * FINCH THERAPEUTICS ANNOUNCES REMOVAL OF FDA CLINICAL HOLD
ON
CP101 IND
    * FINCH THERAPEUTICS GROUP - U.S. FOOD AND DRUG
ADMINISTRATION
(FDA) HAS REMOVED CLINICAL HOLD ON INVESTIGATIONAL NEW DRUG
(IND) APPLICATION FOR CP101
    * FINCH THERAPEUTICS GROUP - FDA LIFTED CLINICAL HOLD
FOLLOWING A
REVIEW OF INFORMATION FINCH PROVIDED RELATED TO ITS SARS-COV-2
SCREENING PROCEDURES
    * FINCH THERAPEUTICS GROUP - EXPECTS TO PROCEED WITH
ENROLLMENT IN
PRISM4 AFTER IT COMPLETES CERTAIN MANUFACTURING ACTIVITIES AND
QUALITY SYSTEM UPDATES
    * SAYS IN PARALLEL WITH THESE ACTIVITIES, WILL CONTINUE TO
WORK
WITH PRISM4 TRIAL SITES TO PREPARE FOR ENROLLMENT
    * FINCH THERAPEUTICS GROUP -TO PROVIDE UPDATE ON ANTICIPATED
TIMING OF BOTH PRISM4 TRIAL AND AUSPIRE PHASE 1B TRIAL OF
FIN-211 DURING Q1 2022 RESULTS

Source text for Eikon:  ID:nGNXdR4NB 
Further company coverage:  FNCH.O 

 ((Reuters.Briefs@thomsonreuters.com;))